Quantcast
Home > Quotes > ALBO

Albireo Pharma, Inc. Common Stock (ALBO) Quote & Summary Data

ALBO 
$25.49
*  
0.81
3.08%
Get ALBO Alerts
*Delayed - data as of Dec. 7, 2018  -  Find a broker to begin trading ALBO now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
50
Today's High / Low
$ 26.73 / $ 24.97
Share Volume
49,883
50 Day Avg. Daily Volume
33,728
Previous Close
$ 26.30
52 Week High / Low
$ 39.8699 / $ 22.64
Market Cap
305,113,465
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.81

Intraday Chart

Shares Traded

Share Volume:
49,883
50 Day Avg. Daily Volume:
33,728

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.09

Trading Range

The current last sale of $25.49 is 12.59% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 26.73 $ 39.8699
 Low: $ 24.97 $ 22.64

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal, or GI, diseases and disorders. The initial target indication for our lead product candidate, A4250, is progressive familial intrahepatic cholestasis, or PFIC, a rare, life-threatening genetic disorder affecting young children for which there is currently no approved drug treatment. We have completed a Phase 2 clinical trial of A4250 in children with chronic cholestasis and pruritus and we plan to conduct a Phase 3 clinical trial in patients with PFIC. In addition to PFIC, we plan to consider conducting future clinical development of A4250 as a treatment for one or more other pediatric cholestatic liver diseases and disorders.  ... More ...  


Risk Grade

Where does ALBO fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 26.30
Open Date:
Dec. 7, 2018
Close Price:
$ 25.49
Close Date:
Dec. 7, 2018

Consensus Recommendation

Analyst Info